| 1 |
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine
Open access |
11 May 2011 |
7,927 |
| 2 |
Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
Claudia Allemani et al. · The Lancet
Open access595 authors |
31 Jan 2018 |
6,323 |
| 3 |
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Daniel J. Klionsky et al. · Autophagy
Open access2,467 authors |
2 Jan 2016 |
6,023 |
| 4 |
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al. · The Lancet
Open access |
13 Feb 2014 |
4,858 |
| 5 |
The repertoire of mutational signatures in human cancer
Ludmil B. Alexandrov et al. · Nature
Open access1,384 authors |
5 Feb 2020 |
3,854 |
| 6 |
Pan-cancer analysis of whole genomes
Lauri A. Aaltonen et al. · Nature
Open access1,324 authors |
5 Feb 2020 |
3,360 |
| 7 |
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen N. Moore et al. · New England Journal of Medicine
Open access |
21 Oct 2018 |
2,927 |
| 8 |
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurélien Marabelle et al. · The Lancet Oncology
Open access |
10 Sep 2020 |
2,600 |
| 9 |
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T.A. van der Graaf et al. · The Lancet
Open access |
May 2012 |
2,123 |
| 10 |
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
Nicole Concin et al. · International Journal of Gynecological Cancer
Open access |
23 Dec 2020 |
2,012 |
| 11 |
B cells are associated with survival and immunotherapy response in sarcoma
Florent Petitprez et al. · Nature
Open access |
15 Jan 2020 |
2,007 |
| 12 |
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
Alan Stuart Coates et al. · Annals of Oncology
Open access |
4 May 2015 |
1,865 |
| 13 |
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Ferdinandos Skoulidis et al. · New England Journal of Medicine
Open access |
4 Jun 2021 |
1,862 |
| 14 |
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David Michael Hyman et al. · New England Journal of Medicine
Open access |
19 Aug 2015 |
1,756 |
| 15 |
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert Louis Coleman et al. · The Lancet
Open access117 authors |
12 Sep 2017 |
1,729 |
| 16 |
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio, Dong‐Wook Kim, Surapol Issaragrisil et al. · New England Journal of Medicine
Open access |
5 Jun 2010 |
1,691 |
| 17 |
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Andreas Hochhaus et al. · Leukemia
Open access |
3 Mar 2020 |
1,556 |
| 18 |
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
François‐Xavier Mahon, Delphine Réa, Joëlle Guilhot et al. · The Lancet Oncology
|
20 Oct 2010 |
1,556 |
| 19 |
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon et al. · The Lancet Oncology
Open access |
12 May 2014 |
1,518 |
| 20 |
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri et al. · The Lancet
Open access |
21 Nov 2012 |
1,428 |
| 21 |
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
Nicoletta Colombo et al. · Annals of Oncology
Open access |
4 Dec 2015 |
1,411 |
| 22 |
Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
Carola Hermine Ries et al. · Cancer Cell
Open access |
Jun 2014 |
1,404 |
| 23 |
Soft‐tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system
Monique Trojani, G Contesso, Jean‐Michel Coindre et al. · International Journal of Cancer
|
15 Jan 1984 |
1,327 |
| 24 |
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher et al. · The Lancet Oncology
Open access |
28 Nov 2016 |
1,218 |
| 25 |
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
Nicoletta Colombo et al. · Annals of Oncology
Open access |
20 Feb 2019 |
1,200 |
| 26 |
The evolutionary history of 2,658 cancers
Moritz Gerstung et al. · Nature
Open access1,441 authors |
5 Feb 2020 |
1,149 |
| 27 |
Screening older cancer patients: first evaluation of the G-8 geriatric screening tool
Carine A. Bellera, M. Rainfray, Simone Mathoulin‐Pélissier et al. · Annals of Oncology
Open access |
16 Jan 2012 |
1,128 |
| 28 |
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
Hyun Cheol Chung, Willeke Ros, Jean‐Pierre Delord et al. · Journal of Clinical Oncology
Open access |
3 Apr 2019 |
1,083 |
| 29 |
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
Gilles Salles et al. · The Lancet
|
21 Dec 2010 |
1,081 |
| 30 |
Patterns of somatic structural variation in human cancer genomes
Yilong Li et al. · Nature
Open access1,411 authors |
5 Feb 2020 |
1,005 |
| 31 |
Magnetic resonance imaging of the breast: Recommendations from the EUSOMA working group
Francesco Sardanelli et al. · European Journal of Cancer
Open access |
23 Mar 2010 |
990 |
| 32 |
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer
Laura Mezquita et al. · JAMA Oncology
Open access |
11 Jan 2018 |
980 |
| 33 |
Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma
Sylvie Négrier, Bernard J. Escudier, Christine Lasset et al. · New England Journal of Medicine
Open access |
30 Apr 1998 |
972 |
| 34 |
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
Andreas Hochhaus, Giuseppe Saglio, Timothy P. Hughes et al. · Leukemia
Open access |
3 Feb 2016 |
861 |
| 35 |
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
Karim S. Fizazi et al. · The Lancet
Open access |
Apr 2022 |
823 |
| 36 |
Efficacy of Selpercatinib in RET -Altered Thyroid Cancers
Lori J. Wirth et al. · New England Journal of Medicine
Open access |
26 Aug 2020 |
801 |
| 37 |
Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing
Isidro Cortés-Ciriano et al. · Nature Genetics
Open access1,407 authors |
5 Feb 2020 |
793 |
| 38 |
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Maha Hussain, Joaquı́n Mateo, Karim S. Fizazi et al. · New England Journal of Medicine
Open access |
20 Sep 2020 |
792 |
| 39 |
Radiotherapy for Glioblastoma in the Elderly
Florence Keime-Guibert, Olivier Louis Chinot, Luc Taillandier et al. · New England Journal of Medicine
|
11 Apr 2007 |
791 |
| 40 |
Identification of molecular apocrine breast tumours by microarray analysis
Pierre Farmer, Herve R. Bonnefoi, Véronique Becette et al. · Oncogene
Open access |
9 May 2005 |
783 |
| 41 |
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
Patrick Schöffski, Sant P. Chawla, Robert G. Maki et al. · The Lancet
Open access |
12 Feb 2016 |
782 |
| 42 |
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer
Nicoletta Colombo, Carien L. Creutzberg, Frédéric Amant et al. · International Journal of Gynecological Cancer
Open access |
5 Dec 2015 |
771 |
| 43 |
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
Olivia Pagani et al. · New England Journal of Medicine
Open access |
Jun 2014 |
756 |
| 44 |
Genomic characterization of metastatic breast cancers
François Bertucci et al. · Nature
|
May 2019 |
755 |
| 45 |
Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
Roberto Ferrara et al. · JAMA Oncology
Open access |
7 Sep 2018 |
751 |
| 46 |
Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas
Jean‐Michel Coindre, Philippe Terrier, Louis Guillou et al. · Cancer
|
2001 |
744 |
| 47 |
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
Emmanuel S. Antonarakis et al. · Journal of Clinical Oncology
Open access |
27 Nov 2019 |
740 |
| 48 |
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Prudence A. Francis et al. · New England Journal of Medicine
Open access |
11 Dec 2014 |
736 |
| 49 |
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
Javier Pascual, Gerhardt Attard, François‐Clément Bidard et al. · Annals of Oncology
Open access |
6 Jul 2022 |
735 |
| 50 |
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
Wolfgang EIERMANN, Stefan Paepke, Justus Appfelstaedt et al. · Annals of Oncology
Open access |
Nov 2001 |
719 |